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Abstract
Background: Ultrasound accelerates thrombolysis with tPA (sonothrombolysis). Ultrasound in the absence of tPA
also accelerates clot break-up (sonolysis). Adding intravenous gaseous microbubbles may potentiate the effect of
ultrasound in both sonothrombolysis and sonolysis. The Norwegian Sonothrombolysis in Acute Stroke Study aims in
a pragmatic approach to assess the effect and safety of contrast enhanced ultrasound treatment in unselected
acute ischaemic stroke patients.
Methods/Design: Acute ischaemic stroke patients ≥18 years, with or without visible arterial occlusion on
computed tomography angiography (CTA) and treatable ≤ 4½ hours after symptom onset, are included in NOR-
SASS. NOR-SASS is superimposed on a separate trial randomising patients with acute ischemic stroke to either
tenecteplase or alteplase (The Norwegian Tenecteplase Stroke Trial NOR-TEST). The NOR-SASS trial has two arms:
1) the thrombolysis-arms (NOR-SASS A and B) includes patients given intravenous thrombolysis (tenecteplase or
alteplase), and 2) the no-thrombolysis-arm (NOR-SASS C) includes patients with contraindications to thrombolysis.
First step randomisation of NOR-SASS A is embedded in NOR-TEST as a 1:1 randomisation to either tenecteplase or
alteplase. Second step NOR-SASS randomisation is 1:1 to either contrast enhanced sonothrombolysis (CEST) or sham
CEST. Randomisation in NOR-SASS B (routine alteplase group) is 1:1 to either CEST or sham CEST. Randomisation of
NOR-SASS C is 1:1 to either contrast enhanced sonolysis (CES) or sham CES. Ultrasound is given for one hour using a 2-MHz
pulsed-wave diagnostic ultrasound probe. Microbubble contrast (SonoVue®) is given as a continuous infusion for ~30 min.
Recanalisation is assessed at 60 min after start of CEST/CES. Magnetic resonance imaging and angiography is performed
after 24 h of stroke onset. Primary study endpoints are 1) major neurological improvement measured with NIHSS score at
24 h and 2) favourable functional outcome defined as mRS 0–1 at 90 days.
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Discussion: NOR-SASS is the first randomised controlled trial designed to test the superiority of contrast enhanced
ultrasound treatment given ≤4½ hours after stroke onset in an unselected acute ischaemic stroke population eligible or not
eligible for intravenous thrombolysis, with or without a defined arterial occlusion on CTA. If a positive effect and safety can
be proven, contrast enhanced ultrasound treatment will be an option for all acute ischaemic stroke patients. EudraCT No
201200032341; www.clinicaltrials.gov NCT01949961.
Keywords: Randomised controlled trial, Acute ischemic stroke, Arterial occlusion, Contrast, Recanalisation, Outcome, Safety,
Sonolysis, Sonothrombolysis, Thrombolysis, Transcranial ultrasound
Background
The common denominator of acute ischaemic stroke is a
thromboembolic arterial occlusion. Intravenous (iv)
thrombolysis with recombinant tissue plasminogen activa-
tor (tPA) is the only proven effective treatment for achiev-
ing arterial recanalisation and does improve outcome if
given within 4½ hours from symptom onset [1]. However,
recanalisation is achieved in only 30-40 % of patients who
undergo thrombolysis [2]. As a result, many patients are
left with a substantial brain damage, with high rates of dis-
ability and mortality [3].
Transcranial ultrasound has been shown in vitro and in
vivo to accelerate thrombolysis [4–6] Ultrasound energy
promotes motion of fluid around the thrombus (micro-
streaming) [7], stimulates arterial dilation, weakens fibrin
cross-links, increases uptake and penetration of tPA and
increases tPA concentration within the thrombus [8–11].
Ultrasound may thus promote tPA delivery despite stag-
nant flow near the occlusion.
In animal studies, ultrasound with frequencies from
27 kHz to 200 kHz increases the thrombolytic effect of
iv thrombolysis [12]. However, low-frequency transcra-
nial ultrasound (<1 MHz) carries an increased risk of
opening the blood–brain barrier (BBB) [13, 14] and is
also associated with productions of undesired standing
waves and cavitation in the brain [15]. Both opening of
the BBB and occurrence of standing waves during low
frequency ultrasound insonation may therefore increase
intracerebral bleedings when combined with iv thromb-
olysis [16, 17]. These results play an important role in
designing a safer application of transcranial ultrasound
in the brain [15].
In humans, ultrasound waves with a frequency of
2 MHz augment clot lysis [18] and recanalization when
combined with iv thrombolysis (sonothrombolysis).
Sonothrombolysis with pulsed-wave 2 MHz ultrasound
is not associated with an increased risk of symptomatic
intracerebral haemorrhage [19, 20], but is associated
with a nearly 3-fold increased likelihood of complete re-
canalization and a 2-fold increased likelihood of func-
tional independence at 3 months [19]. But even 2 MHz
transcranial ultrasound with iv tPA has been shown to
possibly increase the risk of symptomatic bleedings
(TUCSON) [21, 22]. In particular low frequency (300
KHz) ultrasound seems to increase the risk of cerebral
bleedings (TRUMBI) [16]. One randomised study with
transcranial color-coded sonography (TCCS) using a
1.8-MHz Doppler ultrasound probe showed a beneficial
effect on recanalisation and short term outcome in pa-
tients with middle cerebral artery main stem occlusion
(MCA-M1), but with a tendency toward more severe
haemorrhagic transformations in the ultrasound group
[23]. At present, pulsed-wave 2 MHz ultrasound seems
to be the safest approach for sonothrombolysis.
Adding gaseous microbubbles may increase the clot
lysis with and without iv tPA both in vitro and in vivo
[24]. Microbubbles potentiate the effect of ultrasound
[25–27]. When exposed to ultrasound, microbubbles os-
cillate, expand or collapse producing stable cavitation
(sustained bubble activity), which agitates the surround-
ing fluid, produces fluid jets that erode the thrombus
surface, increases the surface area for thrombolytic ac-
tion and accelerates lysis of clots [28–31]. Stable cavita-
tion is associated with increased treatment effect [32],
whereas inertial cavitation leads to microbubble destruc-
tion and decreases ultrasound mediated enhancement of
sonothrombolysis [33]. The effect of ultrasound in sono-
thrombolysis and sonolysis are mainly influenced by
three factors [24]: 1) the size of microbubbles which in-
fluences their resonant frequency [33]; 2) the increasing
attenuation with increasing frequency which limits the
depth of treatment at higher frequencies and 3) the in-
creased risk of standing waves in the cerebral cavity at
lower frequencies [34]. The use of lower ultrasound fre-
quencies has the advantage of improving skull penetration
and position tolerance due to insonation of a larger vol-
ume [24], but may increase the incidence of intracranial
bleedings [16]. Higher ultrasound frequency (2 MHz) is
therefore used in a clinical diagnostic setting. Adding
microbubbles, i.e., iv ultrasound contrast, may induce fur-
ther acceleration of ultrasound enhanced thrombolysis in
acute ischaemic stroke patients, leading to a more
complete recanalisation and better clinical outcome [4].
Contrast enhanced ultrasound insonation of thrombi
in the absence of iv tPA has achieved high rates of reca-
nalisation in animal models [35]. Repeated oscillations of
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the microbubbles around the clot cause an increase in
local temperature due to the absorption of the energy
from the radiated sound field and create further heating
through viscous friction in the blood [36]. Microbubbles
also penetrate the clot and make the tunnels in the fibrin
matrix [24]. Experimental evidence thus indicates that
ultrasound as such can accelerate clot break-up and
lysis, both through mechanical (acoustic cavitation) and
enzymatic mechanisms [28].
A high proportion of acute ischaemic patients are in-
eligible for iv tPA. The effect of ultrasound on the
thrombus in the absence of tPA (sonolysis) is clinically
not well studied, but transcranial 2 MHz ultrasound may
have a lytic effect on the thrombus also without admin-
istration of tPA [22, 37–39]. This ultrasound effect is en-
hanced by echo contrast [31]. The same mechanisms as
in the experimental studies may apply in humans, al-
though the temperature effect may be negligible due to
the ultrasound attenuation through the skull and tissue.
It is nevertheless conceivable that contrast enhanced
sonolysis (CES) may be more effective than ultrasound
alone and may even have a neuroprotective role in acute
ischaemic stroke patients [37, 40, 41]. Previous sono-
thrombolysis studies have focused on the subset of
stroke patients eligible for thrombolysis. A number of
patients have contraindications to thrombolysis and are
left without a therapeutic option. No previous studies
have systematically studied the effect of ultrasound in a
general stroke population not eligible for iv thromboly-
sis. These subsets of patients are in desperate need of a
treatment. NOR-SASS aims at testing a therapeutic op-
tion for these patients.
Alteplase has been used in previous sonothrombolysis
studies. A growing body of evidence indicates that alte-
plase has a negative effect on the ischemic brain, includ-
ing cytotoxicity and increased permeability of the blood
brain barrier facilitating cerebral oedema [42]. An alter-
native thrombolytic therapy that might be easier and
safer to administer could lead to wider acceptance and
use of thrombolytic therapy [43] . Tenecteplase may be
the drug of choice [44]. Tenecteplase is a modified tissue
plasminogen activator that is more fibrin-specific, more
resistant to plasminogen activator inhibitor (PAI), has a
higher thrombolytic potency, with a longer half-life than
alteplase and can therefore be administered as an intra-
venous bolus [43, 45]. No prior studies have investigated
the combination of tenecteplase with contrast enhanced
sonothrombolysis. NOR-SASS aims at testing the safety
of tenecteplase in combination with contrast enhanced
sonothrombolysis.
Previous sonothrombolysis studies were conducted in
patients with an identified thrombus in major intracra-
nial arteries [19, 46]. No previous studies have looked
into the effect of ultrasound in minor stroke in the
absence of a visible thrombus in the major intracranial
arteries. Recanalisation rate following iv thrombolysis is
higher with smaller thrombi in distal arteries [47]. It is
therefore conceivable that ultrasound has even better ef-
fect on small, not visible peripheral arterial thrombi, on
perforator thrombotic occlusions, or even thrombi in
the microcirculation [35]. Several areas of peripheral
vessels are, however, not accessible by ultrasound. Stand-
ard approaches never the less allow insonation of most
of the clinically very relevant MCA-M3/M4, parts of the
anterior and posterior cerebral vascular bed (transtem-
poral window) and the brainstem arteries (transforam-
inal window). Directing the ultrasound beam accurately
onto hypothetical small peripheral occlusions includes a
large degree of uncertainty, but a slight “fanning” move-
ment of the probe increases the probability of covering
the relevant region of interest.
Given the limited effect of iv thrombolysis and the lo-
gistic challenges in endovascular treatment, new thera-
peutic approaches for patients with acute ischaemic
stroke are imperative. This protocol defines a pragmatic
framework for routine ultrasound treatment in acute is-
chaemic stroke.
Hypothesis
We hypothesise that in patients with acute ischaemic
stroke eligible for intravenous thrombolysis, the clinical
effect of contrast enhanced sonothrombolysis (CEST),
given within 4½ hours from symptom onset is superior
to that of intravenous thrombolysis alone. CEST is safe
and effective in both proximal and distal thrombus, and
may achieve higher recanalisation rates and better clin-
ical outcome than intravenous thrombolysis alone.
We further hypothesise that in patients with acute is-
chaemic stroke not eligible for intravenous thrombolysis,
the clinical effect of contrast enhanced sonolysis (CES)
given within 4½ hours from symptom onset is superior
to that of no specific treatment. CES is safe and effective
in both proximal and distal thrombus, and may achieve
higher recanalisation rates and better clinical outcome
than no specific treatment.
Aims of the study
The aims are to assess recanalisation, safety and clinical
outcome of 1) CEST versus sham CEST in patients eli-
gible for intravenous thrombolysis (NOR-SASS A and B)
and 2) CES versus sham CES in patients not eligible for
intravenous thrombolysis (NOR-SASS C).
Design and methods
NOR-SASS is a multi-centre PROBE (prospective ran-
domised open-label blinded endpoint) trial, designed to
establish the superiority of contrast enhanced ultra-
sound treatment versus sham ultrasound treatment in
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consecutively admitted patients with acute ischaemic
stroke. NOR-SASS is superimposed on a trial randomising
patients with acute ischemic stroke to either tenecteplase
or alteplase (The Norwegian Tenecteplase Stroke Trial;
NOR-TEST; ClinicalTrials.gov NCT 01949948). NOR-
SASS A includes patients willing to be randomised to ei-
ther tenecteplase or alteplase in NOR-TEST, NOR-SASS
B includes patients who did not give consent to be rando-
mised and thus receive routine alteplase, and NOR-SASS
C includes patients not eligible for iv thrombolysis.
NOR-SASS compares 1) ultrasound +microbubbles +
randomised alteplase/tenecteplase versus sham ultra-
sound + sham microbubbles (plain saline) + alteplase/
tenecteplase (NOR-SASS A) or 2) ultrasound +micro-
bubbles + non-randomised routine alteplase versus sham
ultrasound + sham microbubbles + alteplase (NOR-SASS
B) and 3) ultrasound +microbubbles versus sham ultra-
sound + sham microbubbles (NOR-SASS C).
NOR-SASS A includes a first step randomisation 1:1
to either tenecteplase or alteplase and a second step ran-
domisation 1:1 to either CEST or sham CEST. NOR-
SASS B (alteplase group) randomisation is 1:1 to either
CEST or sham CEST. NOR-SASS C randomisation is
1:1 to either CES or sham CES (Fig. 1).
Power calculation
Our NORSTROKE data base from before the initiation
of the present study shows that patients treated with
thrombolysis (n = 223) had a 37 % improvement of mean
NIHSS from 8.7 to 5.5 (3.2; SD = 5.9) from admission to
day 7. Based also on thrombolysis series in mild stroke
and on a meta-analysis of sonothrombolysis studies [48],
NOR-SASS aims at detecting a 15 % higher reduction of
mean NIHSS among patients receiving sonothrombolysis
vs. thrombolysis alone (p1 = 0.37; p2 = 0.52, power 0.8) and
will include 276 patients over 3–4 years. The study was
initiated at Haukeland University Hospital, Bergen, in Q3
2012 and is planned to close Q4 2016. An interim analysis
is planned for Q2 2015. Per January 2014, 176 patients are
enrolled.
Patient inclusion and exclusion criteria
All acute ischaemic stroke patients ≥ 18 years admitted
within 4½ hours of symptom onset may be included in
the study. An intracranial arterial occlusion on pre-
treatment computed tomography angiography (CTA) is
not a prerequisite for inclusion since this study also
includes sonothrombolysis/sonolysis of the peripheral
vascular bed and central perforating arteries. Study par-
ticipation is based on informed consent requirements as
approved by the ethics committee. Exclusion criteria are
listed in Table 1.
Study endpoints
Primary study endpoints are 1) neurological improve-
ment (NIHSS score) at 24 h (clinical effect; proof of con-
cept) and 2) functional handicap defined as modified
Rankin Scale (mRS) score 0–1 at 90 days (clinical
Fig. 1 Randomization and flowchart. CEST Contrast enhanced sonothrombolysis with thrombolytic agent. CES Contrast enhanced sonolysis
without thrombolytic agent
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outcome). Secondary study endpoints are 1) haemor-
rhagic transformation (haemorrhagic infarct/haema-
toma), 2) symptomatic cerebral haemorrhage (safety
endpoint), 3) recanalisation at 2 h (optional), 4) recanali-
sation at 24–36 h, 5) MR-DWI lesion volume at 24–36 h
and 6) death.
Assessment methods
Table 2 neurological deficit is documented with National
Institutes of Health Stroke Scale (NIHSS). Function is
documented with mRS and Barthel Index (BI). On admis-
sion, native computed tomography (CT) with CTA is per-
formed for all patients within the therapeutic time
window. Early CT ischaemic signs are semi-quantitatively
assessed using the ASPECTS scoring system [49]. Intra-
cranial middle cerebral artery (MCA) occlusions are tri-
chotomised in none, distal (MCA2), or proximal (MCA1)
occlusion. Other occlusions are defined as appropriate.
Intracranial artery stenosis are described as minor
(≤50 %), moderate (51-70 %) and severe (71-99 %) diam-
eter reduction or occlusion. Magnetic resonance imaging
and angiography (MRI/MRA) or CT/CTA is performed
after 22–36 h to verify the infarct, assess intracranial reca-
nalisation and to detect haemorrhagic transformation.
Radiological assessment is performed by investigators
blinded to the treatment given. Duplex ultrasound exami-
nations are carried out the day after admission. Carotid
stenosis grading is based on flow velocities calculated with
a modified NASCET formula or with the internal-
common carotid ratio (IC-CC ratio).
The amount of ultrasound delivery to the vasculature
cannot be assessed in NOR-SASS. As a surrogate marker
for attenuation through the skull, bone window thick-
ness is measured by a physician blinded to clinical infor-
mation, except for the window of insonation.
Long-term follow-up
Long-term follow-up is performed by standardised ques-
tionnaire as an outpatient clinic visit by a neurologist or
as a telephone interview by a study nurse at 3 months.
Modified Rankin Score, recurrent vascular events, other
diseases or complications, employment state, marriage
state, and mood are registered. Death is checked via the
Norwegian Public Death Registry.
Treatment
Patients are treated according to the Department’s
Standard Operating Procedure (SOP). Specific intraven-
ous or intra-arterial acute treatment, neurosurgery, and
general medical treatment are registered in Norwegian
Stroke Research Registry (NORSTROKE). Thrombolytic
treatment must start ≤4½ hours after acute ischaemic
stroke symptoms onset. Alteplase is given in a dose of
0.9 mg/kg (10 % bolus + 90 % infusion during 1 h), max-
imum dose 90 mg. Tenecteplase is given in a dose of
0.4 mg/kg as bolus, maximum dose 40 mg.
Treatment with ultrasound and microbubbles
(sonothrombolysis or sonolysis)
In patients without an angiographically defined clot,
the investigator judges the clinical picture and applies
ultrasound to the region in which she/he thinks the le-
sion/clot is located, either through the temporal or fo-
raminal window as appropriate. In patients with a
defined occlusion, ultrasound is applied to the region of
the occlusion. All patients are examined and monitored
with transcranial color-coded duplex sonography (TCCS)
and transcranial doppler (TCD) performed by an experi-
enced ultrasonographer working independently from the
treating physician. Intravenous microbubbles (SonoVue®;
10 ml = 80 μl = 45 μg microbubbles) are given as an infu-
sion of 0.3 ml/min for ~30 min, using a BraccoVueJet® in-
fusion pump (BRACCO Imaging, Switzerland).
1. Baseline TCCS examination is performed to locate
the best insonation window, to locate any
occlusion and to assess haemodynamics. A
temporal bone window is defined as good when it
Table 1 Inclusion and exclusion criteria
Inclusion criteria
•Patients >18 years with acute ischaemic stroke, with or without a visible
arterial occlusion, and start of treatment within 4 ½ hours after stroke
onset.
General exclusion criteria
•Patients with premorbid modified Rankin Scale (mRS) score ≥3
•Patients for whom a complete NIH Stroke Score cannot be obtained
•Hemiplegic migraine with no arterial occlusion on baseline CT
•Seizure at stroke onset and no visible occlusion on baseline CT
•Intracranial haemorrhage on baseline CT
•Clinical presentation suggesting subarachnoid haemorrhage even if
baseline CT is normal
•Large areas of hypodense ischaemic changes on baseline CT
Patients with primary endovascular treatment
•Pregnancy or breast feeding, pericarditis, sepsis, any other serious
medical illness likely to interact with treatment, confounding pre-
existent neurological or psychiatric disease, unlikely to complete follow-
up, any investigational drug <14 days
Specific sonothrombolysis/sonolysis exclusion criteria
•Known hypersensitivity or allergy to SonoVue®
•Recent or unstable coronary ischemia or resting angina <7 days
•Acute cardiac insufficiency, cardiac insufficiency class III/IV; serious
cardiac arrhythmias
•Any right-left-shunt, severe pulmonary hypertension (PAP >90 mmHg)
Moderate to severe chronic obstructive pulmonary disease (chronic
obstructive pulmonary disease (COPD), baseline O2 saturation <80 %)
•Acute respiratory distress syndrome (ARDS)
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allows good visualisation of standard landmarks
such as the mesencephalon. A foraminal window
is defined as good when it allows good
visualisation of the basilar artery. Bilateral
assessment of MCA flow velocities may be
undertaken to calculate inter-hemispheric
asymmetry indices [50].
2. Sonothrombolysis or sonolysis is performed with
2 MHz pulsed wave TCD monitoring for 60 min,
using either a hand-held TCD probe or a probe in a
fixation head-band. TCD emitted power output is
set at the maximal achievable level with mechanical
index MI <1.0. The sound of TCD is muted and the
visual display is turned away from the treating
physicians and nurse in order to keep them blinded
to the patients’ study-group assignment [8, 51].
Insonation is performed with continuous slight
“fanning” of the presumed region of interest, with
or without the head band.
3. Recanalisation is assessed at 60 min after start of
sonothrombolysis or sonolysis with TCCS.
Treatment with sham sonothrombolysis or sham
sonolysis
After baseline diagnostic TCCS, the 2 MHz TCD probe
is plugged into an inactive channel. Recanalisation is
assessed using active TCCS at 60 min after start of sham
sonothrombolysis or sonolysis. Sham intravenous con-
trast (NaCl 0.9 %) is given as an iv infusion of 0.3 ml/
min for ~30 min, using a BraccoVueJet® infusion pump.
Care is taken not to display to the treating physicians
which infusion is given.
Outcomes measures
Clinical outcome (neurology and function)
Early (2 h and 24–36 h) clinical outcome, short term
(day 7, or earlier if earlier discharge) and long term (day
90) functional outcome are assessed in a blinded fashion
by a trained stroke nurse or neurologist.
Early clinical outcome is defined by NIHSS score as 1)
absolute reduction in NIHSS at 2 h (ΔNIHSS2 =NIHSS0–
NIHSS2) and at 24 h (ΔNIHSS24 = NIHSS0–NIHSS24) and
as 2) neurological improvement at 24 h (NIHSS24 = 0 or
reduction of ≥4 NIHSS points compared with baseline
NIHSS0). Short term outcome is defined by mRS score
using sliding dichotomy/responder analysis (excellent out-
come mRS 0 with baseline NIHSS ≤7, mRS 0–1 with base-
line NIHSS 8–14, mRS 0–2 with baseline NIHSS ≥15).
Long term outcome is defined by mRS score using 1)
single mRS group comparison; 2) fixed dichotomy (ex-
cellent =mRS 0–1 vs. unfavourable = mRS 2–6 outcome,
and good =mRS 0–2 vs. bad mRS 3–6 outcome); and 3)
sliding dichotomy/responder analysis (excellent outcome
mRS 0 with baseline NIHSS ≤7, mRS 0–1 with baseline
NIHSS 8–14, mRS 0–2 with baseline NIHSS ≥15).
Vascular outcome (recanalisation)
In patients with a defined arterial occlusion on pre-
treatment CTA, early recanalisation is assessed by TCCS
at 60 min. Flow is categorised according to the Thromb-
olysis in Brain Ischaemia (TIBI) grading [52] modified as
0 = absent flow; 1 =minimal flow; 2 = reduced (TIBI 2–3
blunted/dampened) flow; 3 = restored (TIBI 4–5 sten-
otic/normal) flow.
In patients without a defined arterial occlusion on pre-
treatment CTA, haemodynamics are assessed by TCCS at
60 min. In patients with MCA occlusions, inter-
hemispheric asymmetry is calculated comparing time aver-
aged mean flow velocities. Significant peripheral MCA ob-
struction(s) is defined as MCA1 mean flow velocities >21 %
lower than in the contra-lateral MCA1 [50].
Recanalisation at 1 h is by necessity performed un-
blinded by the investigator. Recanalisation at 24-h is
assessed by 24-h MRA (or CTA when MRA is not pos-
sible) by a neurologist and/or neuroradiologist blinded to
all clinical data [53]. Vascular patency is assessed using
adapted Thrombolysis in Myocardial Infarction (TIMI)
criteria [54]. Vessel occlusion status is defined as complete
Table 2 Assessment of patients with acute ischaemic stroke admitted ≤4½ hours
Procedure ↓ Timepoint→ Baseline 1-2 h +24 h (22-36 h) +48 h (42–54 h) Day 7 or earlier discharge Day 90
NIHSS score X X X X X (X)
CT / CTA (MRI / MRA) X X
ECG X
Duplex ultrasound of the neck X
Transcranial duplex ultrasound X X (X) (X)
Modified Rankin Scale (mRS) X X X
Barthel Index (BI) X (X)
Check Recurrent stroke / TIA X
Check Acute coronary heart disease X
(X) optional
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occlusion (TIMI 0), minimal flow (TIMI 1), partial flow
(TIMI 2), or normal flow (TIMI 3). Major vessel recanali-
sation is defined as improvement in baseline-24 h TIMI
score of ≥2, or complete recanalisation.
Brain tissue outcome (infarction)
Tissue damage is assessed by 24-h MRI diffusion
weighted imaging (DWI) or (CT when MRI is not
possible) by a neurologist and/or neuroradiologist
blinded to all clinical data, using ASPECTS scoring
system [49, 55]. In patients without a visible occlusion
on initial CTA the MRI localisation of the lesion is com-
pared with the clinically suspected localisation and will
confirm whether the initial ultrasound was aimed at the
correct region of interest or not.
Safety outcome
Patients are monitored in the stroke unit (or intensive
care unit (ICU) if appropriate) with NIHSS scoring at
close intervals for 24–36 h. Safety is determined by the
incidence of haemorrhagic transformation within 24-h
of treatment on MRI (or CT when MRI is not possible)
by a neurologist and/or neuroradiologist blinded to all
clinical data. Classification of haemorrhagic transform-
ation is left to the discretion of the local investigators. In
case of disagreement, the scans are assessed by the Data
Safety Monitoring Committee.
Haemorrhagic transformation (ECASS criteria) are cate-
gorised as haemorrhagic infarction 1 (HI1 = small pe-
techiae along the margins of the infarct); haemorrhagic
infarction 2 (HI2 = confluent petechiae within the in-
farcted area but no space-occupying effect); parenchymal
haemorrhage 1 (PH1 = blood clots in 30 % or less of the
infarcted area with some slight space-occupying effect);
parenchymal haemorrhage 2 (PH2 = blood clots in more
than 30 % of the infarcted area with substantial space-
occupying effect); and Remote parenchymal haemorrhage
(rPH = bleeding outside the infracted area).
Symptomatic cerebral haemorrhage (sICH) is defined as
local or remote parenchymal haemorrhage type 2 on the
22–36 h post-treatment imaging scan, combined with a
neurological deterioration of 4 points or more on the
NIHSS from baseline or from the lowest NIHSS value be-
tween baseline and 24 h, or leading to death (SITS-MOST
criteria) [56]. In order to facilitate comparison with
published studies, sICH is also assessed according to 1)
NINDS /Cochrane criteria [57] as any haemorrhage plus
any neurological deterioration [NIHSS score ≥1] or that
leads to death within 7 days; 2) ECASS II criteria [58] as
blood at any site in the brain on the CT scan, clinical de-
terioration or adverse events indicating clinical worsening
(drowsiness, increase of hemiparesis) or causing an
increase in the NIHSS score of 4 or more points; and 3)
ECASS III criteria [59] as any apparently extravascular
blood in the brain or within the cranium associated with
clinical deterioration (defined by an increase in the NIHSS
score of 4 or more points) or death, and that is identified as
the predominant cause of the neurological deterioration.
Safety monitoring
The over-all rate of bleeding complications will be com-
pared with historical data from the NORSTROKE Regis-
try 2007–2011, the Pooled analysis of iv alteplase trials
[57], SITS-MOST [60, 61], ECASS III [59] and series on
thrombolysis in patients above 80 years of age [62]. The
mortality rate at 7 days will be compared with historical
data from NORSTROKE 2007–2011.
All Suspected Unexpected Serious Adverse Reactions
(SUSARs) are reported to the Norwegian Medicines
Agency. All serious adverse events (SAE), i.e., bleedings
and deaths, are reported within 24 h to the Executive
working group (EWG). The EWG routinely submits a
safety report to the independent Data Safety Monitoring
Committee (DSMC) after each 40 enrolled patients (20
per group). If the DSMC finds unacceptably increased
sICH with CEST+ thrombolysis as compared with sham
CEST+ thrombolysis, the study may be stopped for fur-
ther analysis. If CEST+ tenecteplase shows a 2 % excess
of sICH as compared with CEST+ alteplase, the tenecte-
plase tier may be stopped and the study may be contin-
ued with only alteplase patients. The same stopping rule
is applied to CES vs. sham CES in patients not eligible
for iv thrombolysis.
Statistical analysis
Statistical design is made in co-operation with the
Centre for Clinical Research, Haukeland University
Hospital. An interim analysis will be performed in Q2
2015. The exact method of the final analysis will be spe-
cified in the Statistical Analysis Plan, which will be
drawn up prior to the closure of the database and the
statistical analysis. The primary analysis is an “intention
to treat” analysis. The results will also be tested in a “per
protocol” analysis. Stratification according to age (≤80
versus >80), baseline NIHSS (≤14 versus >14), time (0–3 h
vs. 3-4½ h), occlusion/no occlusion; correct/incorrect
insonation focus (patients with no visible occlusion on
CTA); atrial fibrillation/no atrial fibrillation will be per-
formed. An analysis excluding MCA1 occlusion and
MCA1- MCA2 occlusions will also be performed.
Temporal bone window thickness will be included in the
analysis. Serious Adverse Events (SAE) and Adverse
Events (AE) will be analysed as appropriate.
Organisation
This study is one of several studies under the Norwegian
Stroke Research Co-operation (NORSTROKE) umbrella.
NOR-SASS is an investigator driven academic trial with
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no bindings to pharmaceutical companies. The trial is
independently monitored by the Western Norway
Health Trust. Patient data are stored as a NORSTROKE
dataset in the European Cerebrovascular Research Infra-
structure (ECRI) database (Oslo University Hospital).
The study is supported by the University of Bergen, the
Norwegian Research Council and the Western Norway
Health Trust.
Approvals
NOR-SASS is performed in accordance with the Declar-
ation of Helsinki, is approved by the Regional Ethics
Committee and the Norwegian Medicines Agency, and
is registered with EudraCT No 201200032341 and in
www.clinicaltrials.gov with Identifier NCT01949961.
The trial is conducted according to Good Clinical
Practice: Consolidated guideline (CPMP/ICH/135/95).
Discussion
Acute ischaemic stroke is a sudden disturbance of the
blood supply to the brain, caused by a blood clot, which
rapidly leads to severe brain damage. Rapid restauration
of blood flow in the occluded intracerebral arteries is the
main goal of acute ischaemic stroke treatment [39].
Rapid reopening of big or small occluded vessels with
regional reperfusions and salvage of brain tissue, is
strongly associated with improved clinical outcome and
reduced mortality [63]. Despite many attempts to find a
new treatment for acute ischaemic stroke in the last
years, iv trombolysis remain the only effective treatment,
but confers clinical benefit in only a limited number of
patients [64]. A new or improved acute treatment is ur-
gently needed.
Contrast enhanced ultrasound treatment, i.e., sono-
thrombolysis (with iv thrombolysis) and sonolysis
(without iv thrombolysis), may be the new therapeutic
option for patients with acute ischaemic stroke.
The CLOTBUST trial (Combined Lysis of Thrombus
in Brain Ischemia Using Transcranial Ultrasound and
Systemic tPA) was a phase II, multicenter international
randomized clinical trial that compared iv tPA vs. iv tPA
plus 2-MHz transcranial Doppler monitoring for 2 h in
acute ischaemic stroke patients with middle cerebral ar-
tery occlusion, within a 3 h time window. A significant
clinical recovery and complete reperfusion of the oc-
cluded artery was noted in 49 % of the patients treated
with iv tPA and ultrasound vs. 30 % of the iv tPA alone,
without an increase of intracerebral bleedings [8].
Lower frequency ultrasound is theoretically more ef-
fective than higher frequency diagnostic ultrasound, be-
cause of better penetration through the skull bone
windows and stronger thrombolytic effect [65]. The
TRUMBI trial (Transcranial Low-Frequency Ultrasound-
Mediated Thrombolysis in Brain Ischemia) was a phase
II, prospective, multicenter nonrandomized trial that
compared standard iv tPA vs. tPA plus low-frequency
pulsed-wave transcranial ultrasound (300-kHz) in pa-
tients with defined arterial occlusion within a six hour
time window. The study was stopped prematurely be-
cause of an unexpected high rate of intracerebral bleed-
ing in the group treated with iv tPA and low frequency
ultrasound [16]. A technical study which simulated
TRUMBI ultrasound delivery, demonstrated that the
peak rarefactional pressure was higher than the inertial
acoustic cavitation threshold in the presence of standing
wave in large areas of the brain, even outside the tar-
geted clot [66] . The technical setting in TRUMBI may
therefore have contributed to increased intracerebral
bleedings in the ultrasound group.
The TUCSON study (Transcranial Ultrasound in Clin-
ical Sonolysis for acute ischaemic stroke) was a phase I-
II, randomised, placebo-controlled, open label, safety,
dose-escalation clinical trial which compared iv tPA vs.
iv tPA plus 2 MHz ultrasound plus microbubbles in pa-
tients with documented intracranial arterial occlusion.
The study showed a trend toward higher early recanali-
sation rate and clinical recovery, but was stopped prema-
turely by the sponsor, because three patients died in the
group treated with iv tPA plus ultrasound plus micro-
bubbles, indicating a possibly increased risk of symptom-
atic bleedings with this combination [22].
Despite TRUMBI and TUCSON trials results, one ex-
perimental animal model of intracerebral hemorrhage
showed that ultrasound in combination with microbub-
bles did not cause additional brain damage during intra-
cerebral hemorrhage [67]. The size of brain hemorrhage,
the amount of apoptosis and extension of brain edema
was similar between the ultrasound plus microbubbles
group and the control group [67]. This was the first ex-
perimental study to show that the combination of ultra-
sound plus microbubbles is safe in cerebral bleedings
and may be used in sonothrombolysis and sonolysis
studies, even before conventional stroke imaging.
Also, a systematic review and meta-analysis of rando-
mised controlled trials and case–control studies [68] from
1970 till 2013, which included 7 randomised control trials
and 3 case control studies showed that sonothrombolysis
and sonolysis is safe, effective (OR of complete recanaliza-
tion (CR) at 1–2 h: 2.95;95 % CI: 1.81-4.81; P < 0.00001)
and patients treated have more than two-fold higher likeli-
hood of favourable long-term outcome (3-months mRS
0–2; OR: 2.20; CI:1.52-3.19; P < 0.0001). These findings
are supported by earlier meta-analyses [19, 46]. Use of
microbubbles in sonothrombolysis or sonolysis is safe and
effective (OR of CR: 2.61; CI: 1.36-4.99; P = 0.004) [68].
NOR-SASS is the first randomised controlled phase III
trial designed to test the superiority of contrast en-
hanced ultrasound treatment given ≤4½ hours after
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stroke onset in a general acute ischaemic stroke popula-
tion eligible or not eligible for iv thrombolysis, and with
or without a defined arterial occlusion on CTA. The pri-
mary aim of NOR-SASS study is to investigate the effect
of a thrombolytic drug, 2 MHz ultrasound and micro-
bubbles in all acute ischaemic patients.
Only 10 % of all acute ischaemic stroke patients within
4.5 h’ time window have a defined occlusion on CTA in
The Bergen NORSTROKE Registry. At present, there
are no data on the effect of sonothrombolysis or sonoly-
sis in patients with less severe stroke in the absence of a
visible thrombus. However, there is no reason to believe
that contrast enhanced ultrasound treatment has inferior
effect on small, not visible thrombi. This group consists
of 90 % of all acute ischaemic stroke patients, but has
not been included in previous sonothrombolysis and
sonolysis clinical trials. The most prominent treatment
effect with complete reversal of microcirculatory ob-
structions has been seen for contrast enhanced sono-
thrombolysis (tPA, ultrasound and microbubbles) vs.
tPA with unenhanced ultrasound [35]. Also, a tissue pro-
tective effect and improved microcirculation has been
observed with the combination of ultrasound and micro-
bubbles [39].
NOR-SASS will add relevant new information on
sonothrombolysis and sonolysis as a treatment for all
acute ischaemic stroke patients within 4.5 h’ time win-
dow, with or without a defined arterial occlusion on
CTA and not only in selected patients. Thrombolysis
with alteplase (Actilyse®), transcranial ultrasound (TCCS,
TCD) and ultrasound contrast (SonoVue®) are part of
routine treatment and assessment. NOR-SASS differs
from routine treatment through the combination of dif-
ferent kinds of thrombolytic drugs plus ultrasound plus
microbubbles.
NOR-SASS includes tenecteplase (Metalyse®), an ap-
proved safe and effective drug for acute myocardial in-
farction, but so far not studied or approved in acute
ischaemic stroke. NOR-SASS is the first sonothromboly-
sis study with tenecteplase. This alternative thrombolytic
therapy, which is easy to use, safe to administer and has
little toxicity may be a new choice for acute ischaemic
stroke treatment with or without ultrasound. The main
aim of NOR-SASS is, however, to study sonothromboly-
sis in patients receiving “any kind of thrombolysis”. The
number of patients receiving tenecteplase will probably
be too low to yield definite effect results, but is consid-
ered to be a phase II safety sub-study.
Microbubbles have their own ability to increase clot
lysis in combination with ultrasound, even in the ab-
sence of a thrombolytic drug [69]. In an animal study,
treatment with microbubbles and transcranial ultra-
sound without tPA (sonolysis) resulted in the same im-
provement as treatment with iv tPA alone and was
associated with significant improvement compared with
untreated animals [35]. This indicates that microbubbles
with ultrasound may have a positive effect similar to that
of iv tPA also in humans. Acute ischaemic stroke pa-
tients with contraindication for iv tPA within a 4.5 h
time window, now untreated and “neglected”, may bene-
fit from sonolysis and have the same clinical effect and
outcome as after iv tPA. NOR-SASS C is the first rando-
mised sonolysis study in all patients with acute ischae-
mic stroke that cannot receive thrombolysis. Even if the
outcome improvement is moderate, sonolysis may still
have a clinically relevant impact in this group.
Thrombolysis in mild stroke
Mild strokes tend to resolve on their own relatively fre-
quently. This will make it more difficult to detect a
meaningful difference between the treatment groups.
Own data indicate that even in mild stroke, thrombolysis
improves outcome [70]. Also, most patients with mild
stroke do not have a visible clot. Stroke mimics mostly
present with mild symptoms, often seemingly related to
the vertebrobasilar circulation. Including mild strokes in
the study therefore probably increases the number of
stroke mimics, which also makes it more difficult to de-
tect a meaningful difference between the treatment
groups. NOR-SASS aims, however, at testing sonothrom-
bolysis in all acute stroke patients and by pragmatic ne-
cessity, NOR-SASS therefore includes also mild strokes,
albeit with a risk of weakening the study.
Delivery of ultrasound to the vasculature
Any stroke trial treatment should ideally be given with
a defined dose. Transcranial ultrasound is attenuated
through the skull and this reduces the effect of ultra-
sound. The attenuation varies between patients and the
“dose” of ultrasound applied in sonothrombolysis is there-
fore not standardised. NOR-SASS is a clinical pragmatic
study and does not include acoustic measurements to as-
sess the effect of attenuation. Measurements of skull
thickness in the area of insonation may, however, serve as
a surrogate marker for skull penetration and thereby also
the dose of ultrasound applied. In patients without a
visualised clot, the investigator judges the clinical picture
in cooperation with the treating physician and decides
where she/he thinks the probable lesion/clot/ischemia
may be. Ultrasound is applied based on this assumption.
MR examination the next day demonstrates the DWI le-
sion(s). The final analysis thereby can include whether or
not the initial ultrasound was aimed at the correct region
of interest or not.
Conclusion
Experimental and human literature supports the view
that contrast enhanced sonothrombolysis and contrast
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enhanced sonolysis improves recanalisation and reperfu-
sion, that it may save tissue at risk, without posing a
threat to the patient’s well-being. If a positive effect and
safety can be proven by NOR-SASS, contrast enhanced
ultrasound treatment may be a pragmatic option for
acute ischaemic stroke patients eligible or not eligible
for intravenous thrombolysis, for patients with or with-
out a defined arterial occlusion on CTA and for those
who do not have access to intra-arterial treatment. And
all evidence points in the same direction: sonothrombo-
lysis and sonolysis represent the next step in non-
invasive treatment of acute ischaemic stroke.
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